Company info:

  • 1-50
  • 2016
  • Foster City, CA
  • 100-500M



Claim company profile

About company:

Apollomics is developing a suite of next-generation therapies to treat cancer. Developing clinical assets requires rigorous preclinical studies and mechanistic and scientific rationale whether the asset is to be used as a monotherapy, a combination therapy or both. Apollomics is using this approach to build a pipeline of therapeutics that fall into three categories: [1] anti-cancer enhancers, [2] tumor inhibitors and [3] immuno-oncology drugs. Apollomic’s lead candidate, APL-101, is a selective and potent, orally-available inhibitor of c-Met, which is overexpressed or mutated in several tumor types. Following successful preclinical and Phase 1 clinical trials, Apollomics is now testing APL-101 in patients with non-small cell lung cancer.


All jobs
See jobs

Claim company profile to post jobs directly on this page and this website.

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com